Trial Profile
An observational retrospective study of fingolimod as a second line therapy in patients with relapse-remitting multiple sclerosis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Feb 2016
Price :
$35
*
At a glance
- Drugs Fingolimod (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 17 Feb 2016 New trial record